Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair

Phase 2/3 Completed 192 enrolled Beijing Tiantan Hospital

RandomizedParallel-groupSingle-blindTreatment

Summary

To explore whether administering tirofiban in stent-assisted coiling/flow diverting treatments for participants with unruptured intracranial aneurysms can reduce new ischemic lesions on postoperative DWI sequences compared to conventional dual antiplatelet therapy.

Timeline

Start: 2024-03-04
Primary completion: 2025-10-09
Completion: 2025-11-09

Outcome

Met primary endpoint

paper Adjunctive tirofiban significantly reduced the median volume of new infarcts (48.6 versus 88.2 mm3, P=0.007) PMID 42283072 ↗

paper and showed a downward trend in the number of new infarction lesions (P=0.046). PMID 42283072 ↗

Publications

Hu X, Jiang Q, Wang N, Liu Q, Li S, Wang P, Ling C, Wang A, Zhang Z, Cao J, Yang X, Wang Y, Xie X, Jing J, Liu L. Tirofiban for Reduction of TEAR: A Phase 2, Randomized, Open-Label, Blinded End Point, Controlled Trial. Stroke. 2026 Jun 12. doi: 10.1161/STROKEAHA.126.056558. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tirofiban	Other / unclassified	0.1 ug/kg	Intravenous
Background	Aspirin	Small molecule	100 mg	—
Background	Clopidogrel	Small molecule	75 mg	—